UK Markets closed

Global Breast Cancer Drugs Market (2021 to 2030) - Players Include Novartis, AstraZeneca and Celgene Among Others

·6-min read

Dublin, Nov. 11, 2021 (GLOBE NEWSWIRE) -- The "Breast Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global breast cancer drugs market as it emerges from the COVID-19 shut down.

The global breast cancer drugs market is expected to grow from $14.25 billion in 2020 to $14.82 billion in 2021 at a compound annual growth rate (CAGR) of 4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $19.49 billion in 2025 at a CAGR of 7.1%.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.

  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.

  • Create regional and country strategies on the basis of local data and analysis.

  • Identify growth segments for investment.

  • Outperform competitors using forecast data and the drivers and trends shaping the market.

  • Understand customers based on the latest market research findings.

  • Benchmark performance against key competitors.

  • Utilize the relationships between key data sets for superior strategizing.

  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the breast cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Breast Cancer Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market.

  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.

  • Market segmentations break down market into sub markets.

  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.

  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Major players in the breast cancer drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca, Eli Lilly and Company, and Celgene Corporation.

The breast cancer drugs market consists of sales of breast cancer drugs and related services. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapy for treating breast cancer.

Manufacturers of breast cancer drugs are governed by various regulatory bodies such as the Food and Drug Administration in the USA and the European Medicines Agency in the European Union. The European medicinces agency (EMA) regulates the market for breast cancer drugs by granting licences to the drugs that have been proven to be safe and clinically effective. The drug is evaluated to understand its benefits and risks and then tested for any post usage effects. The drug can be commercially sold in the European Union upon approval from the EMA. The EMA can also grant a "conditional marketing authorisation"" indicating approval, but can withdraw it if found unsafe or ineffective.

Manufacturers of breast cancer drugs are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge and expand business. For instance, in March 2019, Astrazeneca entered into a partnership deal worth $6.9 billion for the development of a breast cancer drug. According to the deal, the companies will jointly develop the drug trastuzumab deruxtecan and will share development and commercialization costs for the drug worldwide. Novartis collaborated with IBM Watson Health for the development of a solution that can determine drug combinations and sequences for best patient outcomes.

The increasing prevalence of breast cancer is driving the breast cancer drugs market. Breast cancer is the most common type of cancer among women and affects around 2.1 million women each year. According to the World Health Organization, in 2018, an estimated 627,000 women died from breast cancer, accounting for 15% of all cancer related deaths among women. The factors responsible for breast cancer include heredity, age, lifestyle of a person and is more common in developed countries. As the number of people diagnosed with breast cancer rises, the demand for breast cancer drugs increases, thereby driving market growth.

Adverse side effects caused by the use of breast cancer drugs is acting as a restraint on the breast cancer drugs market. Breast cancer drugs can result in long term or short term side effects including headaches, dental issues, osteoporosis, heart problems, cataracts, blood clots, infertility and others. As a result, patients depend on alternate or complementary treatments to deal with the side effects, thereby increasing overall treatment costs. Also, the long lasting nature of some of the side effects discourage the use of breast cancer drugs, affecting market growth.

Key Topics Covered:

1. Executive Summary

2. Breast Cancer Drugs Market Characteristics

3. Breast Cancer Drugs Market Trends And Strategies

4. Impact Of COVID-19 on Breast Cancer Drugs

5. Breast Cancer Drugs Market Size And Growth
5.1. Global Breast Cancer Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers of the Market
5.1.2. Restraints on The Market
5.2. Global Breast Cancer Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers of the Market
5.2.2. Restraints on the Market

6. Breast Cancer Drugs Market Segmentation
6.1. Global Breast Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
6.2. Global Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
6.3. Global Breast Cancer Drugs Market, Segmentation By Sales Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7. Breast Cancer Drugs Market Regional And Country Analysis
7.1. Global Breast Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Breast Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/txmtgb

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting